Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Galderma Laboratories, L.P.
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• Men and women

• 25-70 years

• Diagnosis of papulopustular rosacea

• Eligible for Oracea treatment

Exclusion Criteria:

• Allergies to components of investigational product and/or hypersensitivity to tetracyclines

• Taken systemic therapy directed at improving rosacea, including antibiotics, within 30 days prior to baseline visit

• Used topical rosacea treatment within 30 days prior to baseline visit

• Have active ocular rosacea and/or blepharitis/meibomianitis requiring systemic treatment by an opthalmologist

• Previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics

• Exposed to intense/excessive ultraviolet (UV) radiation within one week prior to baseline and/or who forsee unprotected and intense/excessive UV exposure during the course of the study

• Have planned surgical procedures during the course of the study

• Have used tetracycline antibiotics within 30 days prior to baseline visit or during study

• At risk in terms of precautions, warnings, and contraindications